Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Vestibular Rehabilitation Exercises to Improve Gait, Balance, and Dynamic Visual Acuity in Patients With Vestibular Hypofunction

17 agosto 2026 aggiornato da: Sadaf Anjum, University of Lahore

## Brief Summary

Unilateral vestibular hypofunction (UVH) is a condition characterized by reduced or absent function of one vestibular system and commonly results in dizziness, impaired postural control, gait difficulties, reduced dynamic visual acuity, and increased risk of falls. These impairments can substantially affect functional independence and quality of life. Vestibular rehabilitation therapy (VRT) is an exercise-based physiotherapy approach designed to promote central vestibular compensation through gaze stabilization, habituation, balance, and gait training. However, the evidence comparing the additional benefits of VRT with conventional physiotherapy, particularly in the local population, remains limited. Therefore, this study was conducted to determine and compare the effects of VRT and conventional physiotherapy on balance, gait, dynamic visual acuity, and dizziness-related disability in patients with chronic unilateral vestibular hypofunction.

A single-blinded randomized controlled trial was conducted on 58 participants aged 38-60 years with chronic unilateral vestibular hypofunction. Participants were randomly allocated into an experimental group and a control group, with 29 participants in each group. The experimental group received conventional physiotherapy combined with vestibular-specific rehabilitation, including VOR x1/x2 gaze stabilization, postural stability exercises, and habituation exercises. The control group received conventional physiotherapy consisting of core strengthening and gait training without vestibular-specific interventions. Both groups received treatment twice weekly for eight weeks, with each session lasting approximately 45 minutes. Outcome measures included the Timed Up and Go (TUG) test for functional mobility, Dynamic Visual Acuity (DVA) for visual stability, Dizziness Handicap Inventory (DHI) for dizziness-related disability, and Tandem Romberg testing for balance.

The findings demonstrated greater improvements in the experimental group across the assessed outcomes. TUG performance improved, while DVA and DHI scores showed marked improvement, indicating better visual stability and reduced dizziness-related disability. Romberg performance also improved substantially, reflecting enhanced postural stability and balance control. In comparison, the control group demonstrated smaller or inconsistent changes, particularly in DVA, DHI, and functional mobility. Statistical analysis was performed using non-parametric tests because most study variables were not normally distributed. Within-group comparisons were conducted using the Wilcoxon Signed-Rank Test, while between-group comparisons were performed using the Mann-Whitney U Test.

The study concluded that vestibular rehabilitation therapy is an effective intervention for improving balance, dynamic visual acuity, and dizziness-related disability in patients with unilateral vestibular hypofunction. The experimental group showed greater improvements in postural stability, visual stability, and perceived disability than the conventional physiotherapy group. However, no significant between-group difference was observed for TUG, suggesting that conventional physiotherapy may provide adequate improvement in basic functional mobility. Overall, the findings support incorporating vestibular rehabilitation into physiotherapy management of UVH to enhance sensory integration and functional recovery.

The study recommends early initiation of VRT, individualized exercise programs, and emphasis on home exercises to improve adherence and long-term outcomes. Future research should involve larger samples, multicenter studies, longer follow-up periods, and investigation of optimal exercise dosage and progression.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

58

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000
        • 1-Km Defence Road, near Bhuptian Chowk, Lahore, Pakistan.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • • Age group of 39 - 60 was included in this study. (Grill et al., 2018)

    • Both male and female gender
    • Participants who have chronic condition (past 3 months) (Karabulut et al., 2023)
    • Diagnostic tests:
    • Tandem Romberg with eyes closed (<30s)
    • Timed Up and Go (6 s) - Single leg stance with eyes closed
    • Timed Up and Go (7 s) Tandem Romberg with eyes closed
    • Timed Up and Go (8 s) Standing on foam with eyes closed (Salah et al., 2020)
    • Referred patient were confirmed by dynamic visual acuity test (DVAT)(Vital et al., 2010).

Exclusion Criteria:

  • • Dizziness associated with other neurological conditions (e.g Stroke, diabetic neuropathy) (Yang et al., 2024)

    • Bilateral vestibular hypofunction was excluded (Karabulut et al., 2023)
    • Patients diagnosed with other neurological conditions that may affect balance, gait, or vestibular function, such as multiple sclerosis, Parkinson's disease, cerebellar ataxia etc. (Hall et al., 2022)
    • Participants with cognitive dysfunction (Hall et al., 2022)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Vestibular Rehabilitation Therapy + Conventional Physiotherapy
Participants in this group will receive vestibular rehabilitation therapy in addition to conventional physiotherapy for 8 weeks. Vestibular rehabilitation will include gaze stabilization exercises (VOR x1/x2), habituation exercises, and balance training. Treatment will be provided twice weekly, with each session lasting approximately 45 minutes.
Vestibular rehabilitation therapy consisting of gaze stabilization exercises (VOR x1/x2), habituation exercises, and balance training, administered in addition to conventional physiotherapy. The intervention will be provided twice weekly for 8 weeks, with each session lasting approximately 45 minutes.
Conventional physiotherapy consisting of core strengthening and gait training, administered for 8 weeks. Participants received treatment twice weekly.
Comparatore attivo: Conventional Physiotherapy
Participants in this group will receive conventional physiotherapy alone for 8 weeks. The conventional physiotherapy program will include core strengthening and gait training without the vestibular-specific rehabilitation program.
Vestibular rehabilitation therapy consisting of gaze stabilization exercises (VOR x1/x2), habituation exercises, and balance training, administered in addition to conventional physiotherapy. The intervention will be provided twice weekly for 8 weeks, with each session lasting approximately 45 minutes.
Conventional physiotherapy consisting of core strengthening and gait training, administered for 8 weeks. Participants received treatment twice weekly.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Equilibrio
Lasso di tempo: 6 settimane
6 settimane

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 aprile 2026

Completamento primario (Effettivo)

20 luglio 2026

Completamento dello studio (Effettivo)

20 luglio 2026

Date di iscrizione allo studio

Primo inviato

17 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 agosto 2026

Primo Inserito (Effettivo)

20 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • Arooj Fatima

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi